N-Acetyl-Semax-Amidate
/ Modified heptapeptide derivative of Semax (ACTH(4-10) analog); N-acetylated and C-amidated for stabilityALIAS · NA-Semax-amidate · Acetylated amidated Semax · Ac-Semax-NH2
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. The N-acetylated, C-amidated derivative of Semax has effectively no PubMed-indexed primary literature. Native Semax (Met-Glu-His-Phe-Pro-Gly-Pro — ACTH(4-7) extended with PGP) was developed by the Russian school (Ashmarin, Myasoedov) and has Russian-language clinical and preclinical literature; the doubly-modified derivative does not.
Native Semax is a synthetic heptapeptide based on residues 4–7 of ACTH (Met-Glu-His-Phe) extended with a C-terminal Pro-Gly-Pro for resistance to enzymatic degradation. Reported mechanisms include modulation of BDNF expression, monoaminergic neurotransmission, and neuroprotection in rodent ischaemia models. The N-acetylated, C-amidated derivative is a vendor variant proposed to further extend stability by blocking both peptide termini against exo-peptidase activity; the molecule's pharmacology has not been characterised in published primary literature.
Tier 4. No PubMed-indexed studies of the doubly-modified derivative. The Russian Semax literature (Ashmarin and colleagues, principally 2000s, indexed in journals such as Bioorganicheskaia Khimiia and Zhurnal Nevrologii i Psikhiatrii) describes the parent compound and is not directly transferable.
No formal human safety database for the derivative. Parent Semax tolerability has been reported in the Russian clinical literature; safety read-across to the modified compound is not supported by direct data.
Regulatory status
- FDA status:
- Not FDA-approved
Russian-origin literature without independent Western replication, with the additional layer that the doubly-modified derivative is not represented in the Russian published record either. Vendor product identity and pharmacology are not externally verifiable.